NanoMosaic, the leader in next-generation digital proteomic interrogation technology, won the prestigious NEVY, New England Venture Capital award, for, \"Emerging MedTech Company of the Year.\" The award was presented to NanoMosaic at the sold-out awards ceremony at the House of Blues in Bosto NanoMosaic, the leader in next-generation digital proteomic interrogation technology, won the prestigious NEVY, New England Venture Capital award, for, \"Emerging MedTech Company of the Year.\" The award was presented to NanoMosaic at the sold-out awards ceremony at the House of Blues in Boston The company, which announced its oversubscribed Series A round of $40.75MM in November 2021

• Has multiple published peer reviewed papers with prestigious hospitals and thought leaders
• Had An IRB approved study at Massachusetts General Hospital that was based on the Tessie to identify biomarkers for post-operative delirium
• Is working with the FDA on 510K approval for its system for diagnostic testing implementation
• Has developed an impressive, and rapidly growing system install base in the life science research field
• Is completing construction on a 32K square foot facility on Winter Street in Waltham, MA in Q1 2023

The NanoMoasic Tessie™ platform allows for streamlined sample preparation, whereby plasma is diluted and deposited directly onto the Tessie chip for analysis with results for 96 samples obtained in ~13 minutes.  The simplicity in sample preparation removes molecular biases and provides a straightforward and seamless workflow for lab and diagnostic technicians.